A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals with Fragile X Syndrome
Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X syndrome (FXS).
Q: Why do this study?
We are attempting to further assess Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties which individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.
Q: What will the participants do?
Commit to a four-month study which includes three clinic visits, and five phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.
Q: Who Can Participate?
Individuals aged 6-25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).
Q: Where is the study being conducted?
There are two sites: the University of Alberta and Ste Justine in Montreal. Travel expenses will be reimbursed.
The principal investigator of this study is Dr. Francois Bolduc, MD, PhD, FRCPC, in the Department of Pediatrics at the University of Alberta.
If you’d like to learn more or apply for this opportunity, please fill out the form to send your contact information to the study coordinators.
View More Opportunities
A survey to measure levels of behavior. When someone with FXS is experiencing anxiety, describe what you see and hear, and how the experience impacts your/their quality of life.
The goal of the study is to learn more about how certain abilities, types of experiences, and biology affect language abilities in adulthood for both males and females with Fragile X syndrome.